Keywords
Last Name
Institution

SUZANNE A W FUQUA

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
DivisionMedicine-Hematology & Oncology
AddressOne Baylor Plaza
Houston TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentBreast Center
    DivisionBreast Cancer Center

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular & Cellular Biology
    DivisionMolecular & Cellular Biology


    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gelsomino L, Panza S, Giordano C, Barone I, Gu G, Spina E, Catalano S, Fuqua S, Andò S. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. Cancer Lett. 2018 Apr 24; 428:12-20. PMID: 29702197.
      View in: PubMed
    2. Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S, Fuqua SAW. Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2017 Apr 24. PMID: 28439737.
      View in: PubMed
    3. Bado I, Gugala Z, Fuqua SA, Zhang XH. Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene. 2017 Apr 03. PMID: 28368409.
      View in: PubMed
    4. Carron EC, Homra S, Rosenberg J, Coffelt SB, Kittrell F, Zhang Y, Creighton CJ, Fuqua SA, Medina D, Machado HL. Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget. 2017 Aug 01; 8(31):50731-50746. PMID: 28881599.
      View in: PubMed
    5. Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016 Dec; 31:97-103. PMID: 27883943.
      View in: PubMed
    6. Fuqua SA, Rechoum Y, Gu G. ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg". JAMA Oncol. 2016 Oct 1; 2(10):1315-1316. PMID: 27532824.
      View in: PubMed
    7. Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O'Shaughnessy J. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016; 1(4):e000072. PMID: 27843626.
      View in: PubMed
    8. Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 Aug; 158(3):441-54. PMID: 27393618; PMCID: PMC4963453.
    9. Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S, Fuqua SA. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016 Jun; 157(2):253-65. PMID: 27178332.
      View in: PubMed
    10. Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, Fuqua SA, Andò S. Erratum to: Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat. 2016 Apr; 156(2):409. PMID: 27008182.
      View in: PubMed
    11. den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PH. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Res. 2016 Feb 26. PMID: 26921331.
      View in: PubMed
    12. Gu G, Fuqua SA. ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action. Clin Cancer Res. 2016 Mar 1; 22(5):1034-6. PMID: 26700205; PMCID: PMC4775407 [Available on 03/01/17].
    13. Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERa-positive breast cancer. Breast Cancer Res Treat. 2015 Oct 20. PMID: 26487496.
      View in: PubMed
    14. Gu G, Gelsomino L, Covington KR, Beyer AR, Wang J, Rechoum Y, Huffman K, Carstens R, Andò S, Fuqua SA. Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):535-45. PMID: 25820519; PMCID: PMC4418174.
    15. Covington KR, Fuqua SA. Role of MTA2 in human cancer. Cancer Metastasis Rev. 2014 Dec; 33(4):921-8. PMID: 25394532; PMCID: PMC4425804.
    16. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 1; 21(7):1688-98. PMID: 25208879; PMCID: PMC4362882.
    17. Rechoum Y, Rovito D, Iacopetta D, Barone I, Andò S, Weigel NL, O'Malley BW, Brown PH, Fuqua SA. AR collaborates with ER? in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85. PMID: 25178514; PMCID: PMC4337991.
    18. Catalano S, Giordano C, Panza S, Chemi F, Bonofiglio D, Lanzino M, Rizza P, Romeo F, Fuqua SA, Maggiolini M, Andò S, Barone I. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat. 2014 Jul; 146(2):273-85. PMID: 24928526.
      View in: PubMed
    19. Fuqua SA, Gu G, Rechoum Y. Estrogen receptor (ER) ? mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat. 2014 Feb; 144(1):11-9. PMID: 24487689; PMCID: PMC4123761.
    20. Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SA. Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2013 Sep 28. PMID: 24077732.
      View in: PubMed
    21. De Amicis F, Russo A, Avena P, Santoro M, Vivacqua A, Bonofiglio D, Mauro L, Aquila S, Tramontano D, Fuqua SA, Andò S. In vitro mechanism for downregulation of ER-? expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res. 2013 May; 57(5):840-53. PMID: 23322423; PMCID: PMC4642730.
    22. Eswaran J, Horvath A, Godbole S, Reddy SD, Mudvari P, Ohshiro K, Cyanam D, Nair S, Fuqua SA, Polyak K, Florea LD, Kumar R. RNA sequencing of cancer reveals novel splicing alterations. Sci Rep. 2013; 3:1689. PMID: 23604310; PMCID: PMC3631769.
    23. Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R. Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep. 2013; 3:2256. PMID: 23884293; PMCID: PMC3722564.
    24. Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, De Amicis F, Fuqua SA, Catalano S, Andò S. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol. 2013 Jun; 7(3):379-91. PMID: 23228483.
      View in: PubMed
    25. Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013 Jul 4; 32(27):3274-85. PMID: 22907432; PMCID: PMC3505272.
    26. Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA, Lange CA. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012; 14(3):R95. PMID: 22697792; PMCID: PMC3446358.
    27. Bartella V, Rizza P, Barone I, Zito D, Giordano F, Giordano C, Catalano S, Mauro L, Sisci D, Panno ML, Fuqua SA, Andò S. Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat. 2012 Jul; 134(2):569-81. PMID: 22622808; PMCID: PMC4484599.
    28. Eswaran J, Cyanam D, Mudvari P, Reddy SD, Pakala SB, Nair SS, Florea L, Fuqua SA, Godbole S, Kumar R. Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep. 2012; 2:264. PMID: 22355776; PMCID: PMC3278922.
    29. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Bonofiglio D, Bossi G, Covington KR, Fuqua SA, Andò S. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012 Mar 15; 72(6):1416-27. PMID: 22282662; PMCID: PMC4123759.
    30. Iacopetta D, Rechoum Y, Fuqua SA. The Role of Androgen Receptor in Breast Cancer. Drug Discov Today Dis Mech. 2012; 9(1-2):e19-e27. PMID: 26568765.
      View in: PubMed
    31. Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, Badwe RA, Fuqua S, Wallon M, Prendergast GC, Kumar R. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011 Dec 1; 71(23):7259-69. PMID: 22006997; PMCID: PMC3617573.
    32. Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, Ando S, Fuqua SA. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011 Oct 15; 17(20):6510-21. PMID: 21878538; PMCID: PMC3281508.
    33. Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27. PMID: 21792626; PMCID: PMC4477822.
    34. De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano D, Fuqua SA, Andò S. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011 Oct; 25(10):3695-707. PMID: 21737614; PMCID: PMC3177579.
    35. Giordano C, Catalano S, Panza S, Vizza D, Barone I, Bonofiglio D, Gelsomino L, Rizza P, Fuqua SA, Andò S. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene. 2011 Sep 29; 30(39):4129-40. PMID: 21499302; PMCID: PMC4482257.
    36. Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA. Loss of Rho GDI? and resistance to tamoxifen via effects on estrogen receptor ?. J Natl Cancer Inst. 2011 Apr 6; 103(7):538-52. PMID: 21447808; PMCID: PMC3071355.
    37. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13. PMID: 21123450; PMCID: PMC3140407.
    38. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010 May 15; 16(10):2702-8. PMID: 20427689; PMCID: PMC4477803.
    39. Ohshiro K, Mudvari P, Meng QC, Rayala SK, Sahin AA, Fuqua SA, Kumar R. Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol Endocrinol. 2010 May; 24(5):914-22. PMID: 20304996; PMCID: PMC2870933.
    40. Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, Andò S, Fuqua SA. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene. 2010 Apr 22; 29(16):2404-14. PMID: 20101208; PMCID: PMC2922934.
    41. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG, Tomita YA, Rosen EM. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol. 2010 Jan; 24(1):76-90. PMID: 19887647; PMCID: PMC2802901.
    42. Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA. A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions. Breast Cancer Res Treat. 2010 Jul; 122(2):381-93. PMID: 19842032; PMCID: PMC4151536.
    43. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Andò S, Maggiolini M. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol. 2009 Nov; 23(11):1815-26. PMID: 19749156.
      View in: PubMed
    44. Chang JC, Hilsenbeck SG, Fuqua SA. Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703. PMID: 19637041.
      View in: PubMed
    45. Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA, Andò S. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009 Sep; 175(3):1270-80. PMID: 19644018; PMCID: PMC2731145.
    46. Herynk MH, Lewis MT, Hopp TA, Medina D, Corona-Rodriguez A, Cui Y, Beyer AR, Fuqua SA. Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice. Oncogene. 2009 Sep 10; 28(36):3177-87. PMID: 19561644; PMCID: PMC4484624.
    47. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11. PMID: 19533338; PMCID: PMC2995248.
    48. Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S, Fuqua SA. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 2009 Jun 1; 69(11):4724-32. PMID: 19487288; PMCID: PMC2804866.
    49. Giordano C, Cui Y, Barone I, Ando S, Mancini MA, Berno V, Fuqua SA. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat. 2010 Jan; 119(1):71-85. PMID: 19205871; PMCID: PMC4482256.
    50. De Amicis F, Zupo S, Panno ML, Malivindi R, Giordano F, Barone I, Mauro L, Fuqua SA, Andò S. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol Endocrinol. 2009 Apr; 23(4):454-65. PMID: 19147702; PMCID: PMC2725766.
    51. Herynk MH, Selever J, Thirugnanasampanthan J, Cui Y, Fuqua SA. Hormone Action and Clinical Significance of the Estrogen Receptor ?. Cancer Treat Res. 2009; 147:1-16. PMID: 21461833.
      View in: PubMed
    52. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, Fuqua SA. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 1; 13(11):3235-43. PMID: 17545528; PMCID: PMC4484622.
    53. Herynk MH, Fuqua SA. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol. 2007; 608:130-43. PMID: 17993238.
      View in: PubMed
    54. Medina D, Kittrell FS, Tsimelzon A, Fuqua SA. Inhibition of mammary tumorigenesis by estrogen and progesterone in genetically engineered mice. Ernst Schering Found Symp Proc. 2007; (1):109-26. PMID: 18540570.
      View in: PubMed
    55. Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther. 2006 Dec; 5(12):3023-31. PMID: 17172405.
      View in: PubMed
    56. Ramos CA, Bowman TA, Boles NC, Merchant AA, Zheng Y, Parra I, Fuqua SA, Shaw CA, Goodell MA. Evidence for diversity in transcriptional profiles of single hematopoietic stem cells. PLoS Genet. 2006 Sep 29; 2(9):e159. PMID: 17009876; PMCID: PMC1584276.
    57. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 1; 66(11):5950-9. PMID: 16740736; PMCID: PMC4484848.
    58. Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SA. Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol. 2006 Sep; 20(9):2020-35. PMID: 16645043; PMCID: PMC4484605.
    59. Singh RR, Barnes CJ, Talukder AH, Fuqua SA, Kumar R. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res. 2005 Nov 15; 65(22):10594-601. PMID: 16288053.
      View in: PubMed
    60. Sommer S, Cui Y, Brewer G, Fuqua SA. The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J Steroid Biochem Mol Biol. 2005 Nov; 97(3):219-29. PMID: 16289864.
      View in: PubMed
    61. Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res. 2005 Oct 15; 11(20):7579-85. PMID: 16243834.
      View in: PubMed
    62. Chang JC, Hilsenbeck SG, Fuqua SA. The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4. PMID: 15987438; PMCID: PMC1143565.
    63. Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24. PMID: 15714204; PMCID: PMC2361866.
    64. Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 1; 23(4):931-2; author reply 932-3. PMID: 15681552.
      View in: PubMed
    65. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004 Dec 15; 64(24):9199-208. PMID: 15604293.
      View in: PubMed
    66. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9. PMID: 15569979.
      View in: PubMed
    67. deGraffenried LA, Hopp TA, Valente AJ, Clark RA, Fuqua SA. Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. Breast Cancer Res Treat. 2004 May; 85(2):111-20. PMID: 15111769.
      View in: PubMed
    68. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60. PMID: 15102680.
      View in: PubMed
    69. Fuqua SA, Chang JC, Hilsenbeck SG. Genomic approaches to understanding and treating breast cancer. Breast Dis. 2004; 19:35-46. PMID: 15687696.
      View in: PubMed
    70. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 5; 95(5):353-61. PMID: 12618500.
      View in: PubMed
    71. Benz C, Clark G, Conzen S, Dorn R, Fuqua S, Gralow J, Greene G, Heimann R, Hellman S, Lippman M, Rosen N, Weiner L. Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat. 2003 Mar; 78(1):127-31. PMID: 12611465.
      View in: PubMed
    72. Xian Ma Y, Fan S, Xiong J, Yuan RQ, Meng Q, Gao M, Goldberg ID, Fuqua SA, Pestell RG, Rosen EM. Role of BRCA1 in heat shock response. Oncogene. 2003 Jan 9; 22(1):10-27. PMID: 12527903.
      View in: PubMed
    73. deGraffenried LA, Hilsenbeck SG, Fuqua SA. Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol. 2002 Sep; 82(1):7-18. PMID: 12429135.
      View in: PubMed
    74. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Jänne OA, Pestell RG. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol. 2002 May; 22(10):3373-88. PMID: 11971970; PMCID: PMC133781.
    75. Fuqua SA, Cui Y. Targeting the estrogen receptor in clinical breast cancer. Breast Dis. 2002; 15:3-11. PMID: 15687641.
      View in: PubMed
    76. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PMID: 11916222.
      View in: PubMed
    77. Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001 Oct; 6(4):407-17. PMID: 12013530.
      View in: PubMed
    78. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001 Oct; 11(5):339-52. PMID: 11562176.
      View in: PubMed
    79. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem. 2001 Jul 27; 276(30):27907-12. PMID: 11353774.
      View in: PubMed
    80. Hansen RK, Parra I, Hilsenbeck SG, Himelstein B, Fuqua SA. Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. Biochem Biophys Res Commun. 2001 Mar 23; 282(1):186-93. PMID: 11263990.
      View in: PubMed
    81. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem. 2001 May 25; 276(21):18375-83. PMID: 11279135.
      View in: PubMed
    82. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001 Mar; 8(1):47-61. PMID: 11350726.
      View in: PubMed
    83. Zhou Q, Hopp T, Fuqua SA, Steeg PS. Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett. 2001 Jan 10; 162(1):3-17. PMID: 11121857.
      View in: PubMed
    84. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 6; 92(23):1926-34. PMID: 11106684.
      View in: PubMed
    85. Su JL, McKee DD, Ellis B, Kadwell SH, Wisely GB, Moore LB, Triantafillou JA, Kost TA, Fuqua S, Moore JT. Production and characterization of an estrogen receptor beta subtype-specific mouse monoclonal antibody. Hybridoma. 2000 Dec; 19(6):481-7. PMID: 11152400.
      View in: PubMed
    86. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 1; 60(15):4026-9. PMID: 10945602.
      View in: PubMed
    87. Koduri S, Fuqua SA, Poola I. Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J Cancer Res Clin Oncol. 2000 May; 126(5):291-7. PMID: 10815765.
      View in: PubMed
    88. Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81. PMID: 10707955.
      View in: PubMed
    89. Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 1999 Nov 1; 59(21):5425-8. PMID: 10554010.
      View in: PubMed
    90. Lemieux P, Harvey J, Guise T, Dallas M, Oesterreich S, Yin Jj, Selander K, Fuqua S. Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo. J Bone Miner Res. 1999 Sep; 14(9):1570-5. PMID: 10469286.
      View in: PubMed
    91. Oesterreich S, Fuqua SA. Tumor suppressor genes in breast cancer. Endocr Relat Cancer. 1999 Sep; 6(3):405-19. PMID: 10516854.
      View in: PubMed
    92. O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DC. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7. PMID: 10451444.
      View in: PubMed
    93. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat. 1999 Jul; 56(2):187-96. PMID: 10573111.
      View in: PubMed
    94. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 3; 91(5):453-9. PMID: 10070945.
      View in: PubMed
    95. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998 May 6; 90(9):697-703. PMID: 9586667.
      View in: PubMed
    96. Eskenazi AE, Powers J, Pinkas J, Oesterreich S, Fuqua SA, Frantz CN. Induction of heat shock protein 27 by hydroxyurea and its relationship to experimental metastasis. Clin Exp Metastasis. 1998 Apr; 16(3):283-90. PMID: 9568646.
      View in: PubMed
    97. Hopp TA, Fuqua SA. Estrogen receptor variants. J Mammary Gland Biol Neoplasia. 1998 Jan; 3(1):73-83. PMID: 10819506.
      View in: PubMed
    98. Oesterreich S, Lee AV, Sullivan TM, Samuel SK, Davie JR, Fuqua SA. Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells. J Cell Biochem. 1997 Nov 1; 67(2):275-86. PMID: 9328833.
      View in: PubMed
    99. Hansen RK, Oesterreich S, Lemieux P, Sarge KD, Fuqua SA. Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells. Biochem Biophys Res Commun. 1997 Oct 29; 239(3):851-6. PMID: 9367858.
      View in: PubMed
    100. Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997 Aug 15; 57(16):3486-93. PMID: 9270017.
      View in: PubMed
    101. Wang M, Dotzlaw H, Fuqua SA, Murphy LC. A point mutation in the human estrogen receptor gene is associated with the expression of an abnormal estrogen receptor mRNA containing a 69 novel nucleotide insertion. Breast Cancer Res Treat. 1997 Jun; 44(2):145-51. PMID: 9232273.
      View in: PubMed
    102. Castles CG, Oesterreich S, Hansen R, Fuqua SA. Auto-regulation of the estrogen receptor promoter. J Steroid Biochem Mol Biol. 1997 Jun; 62(2-3):155-63. PMID: 9393950.
      View in: PubMed
    103. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997 Apr 1; 57(7):1244-9. PMID: 9102207.
      View in: PubMed
    104. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SA. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23. PMID: 9702938.
      View in: PubMed
    105. Zhang QX, Hilsenbeck SG, Fuqua SA, Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60. PMID: 9010317.
      View in: PubMed
    106. Castles CG, Allred DC, Krieg SL, Benedix MG, Fuqua SA. RNA from air-dried frozen sections for RT-PCR and differential display. Biotechniques. 1996 Sep; 21(3):425-8. PMID: 8879580.
      View in: PubMed
    107. Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206. PMID: 9816288.
      View in: PubMed
    108. Oesterreich S, Hickey E, Weber LA, Fuqua SA. Basal regulatory promoter elements of the hsp27 gene in human breast cancer cells. Biochem Biophys Res Commun. 1996 May 6; 222(1):155-63. PMID: 8630062.
      View in: PubMed
    109. Lemieux P, Fuqua S. The role of the estrogen receptor in tumor progression. J Steroid Biochem Mol Biol. 1996 Jan; 56(1-6 Spec No):87-91. PMID: 8603051.
      View in: PubMed
    110. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11. PMID: 7573366; PMCID: PMC1871005.
    111. Fuqua SA, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat. 1995 Sep; 35(3):233-41. PMID: 7579493.
      View in: PubMed
    112. Klotz DM, Castles CG, Fuqua SA, Spriggs LL, Hill SM. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem Biophys Res Commun. 1995 May 16; 210(2):609-15. PMID: 7755640.
      View in: PubMed
    113. Castles CG, Klotz DM, Fuqua SA, Hill SM. Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines. Br J Cancer. 1995 May; 71(5):974-80. PMID: 7734323; PMCID: PMC2033773.
    114. Wolf DM, Fuqua SA. Mechanisms of action of antiestrogens. Cancer Treat Rev. 1995 May; 21(3):247-71. PMID: 7656267.
      View in: PubMed
    115. Wiltschke C, Fuqua SA. Clinical relevance of estrogen receptor variants in breast cancer. Trends Endocrinol Metab. 1995 Apr; 6(3):77-82. PMID: 18406686.
      View in: PubMed
    116. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SA. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9. PMID: 9815968.
      View in: PubMed
    117. Fuqua SA. Estrogen receptor mutagenesis and hormone resistance. Cancer. 1994 Aug 1; 74(3 Suppl):1026-9. PMID: 8039136.
      View in: PubMed
    118. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 1994 Jul 15; 54(14):3752-7. PMID: 8033095.
      View in: PubMed
    119. Auchus RJ, Fuqua SA. Clinical syndromes of hormone receptor mutations: hormone resistance and independence. Semin Cell Biol. 1994 Apr; 5(2):127-36. PMID: 8068885.
      View in: PubMed
    120. Auchus RJ, Fuqua SA. Hormone-nuclear receptor interactions in health and disease. The oestrogen receptor. Baillieres Clin Endocrinol Metab. 1994 Apr; 8(2):433-49. PMID: 7522434.
      View in: PubMed
    121. Auchus RJ, Fuqua SA. Prognostic factors and variant estrogen receptor RNAs in clinical breast cancer. Nucl Med Biol. 1994 Apr; 21(3):449-54. PMID: 9234308.
      View in: PubMed
    122. Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994 Mar 15; 13(6):1331-40. PMID: 7907978; PMCID: PMC394949.
    123. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CK. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74. PMID: 8120545.
      View in: PubMed
    124. Allred DC, O'Connell P, Fuqua SA, Osborne CK. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):13-8. PMID: 7819582.
      View in: PubMed
    125. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):5-12. PMID: 7819586.
      View in: PubMed
    126. Allred DC, Elledge R, Clark GM, Fuqua SA. The p53 tumor-suppressor gene in human breast cancer. Cancer Treat Res. 1994; 71:63-77. PMID: 7946959.
      View in: PubMed
    127. Encarnacion CA, Fuqua SA. Estrogen receptor variants in breast cancer. Cancer Treat Res. 1994; 71:97-109. PMID: 7946961.
      View in: PubMed
    128. Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55. PMID: 7819585.
      View in: PubMed
    129. Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71. PMID: 7819588.
      View in: PubMed
    130. Fuqua SA, Benedix MG, Krieg S, Weng CN, Chamness GC, Oesterreich S. Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells. Breast Cancer Res Treat. 1994; 32(2):177-86. PMID: 7865847.
      View in: PubMed
    131. Zhang QX, Borg A, Fuqua SA. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 1993 Dec 15; 53(24):5882-4. PMID: 8261397.
      View in: PubMed
    132. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993 Oct 6; 85(19):1558-70. PMID: 8411230.
      View in: PubMed
    133. Wiebe VJ, Osborne CK, Fuqua SA, DeGregorio MW. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol. 1993 Jun; 14(3):173-88. PMID: 8397846.
      View in: PubMed
    134. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 1993 Apr 7; 85(7):570-4. PMID: 8455204.
      View in: PubMed
    135. Fuqua SA, Chamness GC, McGuire WL. Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993 Feb; 51(2):135-9. PMID: 8440747.
      View in: PubMed
    136. Fuqua SA, Allred DC, Auchus RJ. Expression of estrogen receptor variants. J Cell Biochem Suppl. 1993; 17G:194-7. PMID: 8007697.
      View in: PubMed
    137. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC. William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat. 1993; 27(1-2):95-102. PMID: 8260732.
      View in: PubMed
    138. Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46. PMID: 8251648.
      View in: PubMed
    139. Fuqua SA, Allred DC, Elledge RM, Krieg SL, Benedix MG, Nawaz Z, O'Malley BW, Greene GL, McGuire WL. The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202. PMID: 8219256.
      View in: PubMed
    140. Allred DC, O'Connell P, Fuqua SA. Biomarkers in early breast neoplasia. J Cell Biochem Suppl. 1993; 17G:125-31. PMID: 8007690.
      View in: PubMed
    141. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993; 26(3):225-35. PMID: 8251647.
      View in: PubMed
    142. McGuire WL, Chamness GC, Fuqua SA. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):243-7. PMID: 1525064.
      View in: PubMed
    143. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992 Jul 1; 52(13):3648-54. PMID: 1617638.
      View in: PubMed
    144. Fuqua SA. Where is the lesion in hormone-independent breast cancer? J Natl Cancer Inst. 1992 Apr 15; 84(8):554-5. PMID: 1556761.
      View in: PubMed
    145. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6. PMID: 1728420.
      View in: PubMed
    146. McGuire WL, Chamness GC, Fuqua SA. Abnormal oestrogen receptor in clinical breast cancer. Eur J Cancer. 1992; 28(2-3):309-10. PMID: 1591044.
      View in: PubMed
    147. McGuire WL, Chamness GC, Fuqua SA. The importance of normal and abnormal oestrogen receptor in breast cancer. Cancer Surv. 1992; 14:31-40. PMID: 1423328.
      View in: PubMed
    148. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov; 5(11):1571-7. PMID: 1779964.
      View in: PubMed
    149. Fuqua SA, Hill SM, Chamness GC, Benedix MG, Greene GL, O'Malley BW, McGuire WL. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst. 1991 Aug 21; 83(16):1157-60. PMID: 1679459.
      View in: PubMed
    150. Borg A, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Olsson H, Killander D, McGurie WL. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer. 1991 Jan; 63(1):136-42. PMID: 1989653; PMCID: PMC1971653.
    151. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 1; 51(1):105-9. PMID: 1988075.
      View in: PubMed
    152. Fuqua SA, Fitzgerald SD, McGuire WL. A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts. Biotechniques. 1990 Aug; 9(2):206-11. PMID: 1698071.
      View in: PubMed
    153. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SA, Killander D, McGuire WL. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15; 50(14):4332-7. PMID: 1973070.
      View in: PubMed
    154. Falette NS, Fuqua SA, Chamness GC, Cheah MS, Greene GL, McGuire WL. Estrogen receptor gene methylation in human breast tumors. Cancer Res. 1990 Jul 1; 50(13):3974-8. PMID: 2354445.
      View in: PubMed
    155. Schneider SL, Fuqua SA, Speeg KV, Tandon AK, McGuire WL. Isolation and characterization of an adriamycin-resistant breast tumor cell line. In Vitro Cell Dev Biol. 1990 Jun; 26(6):621-8. PMID: 1972704.
      View in: PubMed
    156. Fuqua SA, Falette NF, McGuire WL. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst. 1990 May 16; 82(10):858-61. PMID: 2332903.
      View in: PubMed
    157. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K, Marshall M, Li CH. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov; 3(11):1701-9. PMID: 2558302.
      View in: PubMed
    158. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol. 1989 Aug; 7(8):1129-36. PMID: 2569033.
      View in: PubMed
    159. Fuqua SA, Blum-Salingaros M, McGuire WL. Induction of the estrogen-regulated "24K" protein by heat shock. Cancer Res. 1989 Aug 1; 49(15):4126-9. PMID: 2743305.
      View in: PubMed
    160. McGuire SE, Fuqua SA, Naylor SL, Helin-Davis DA, McGuire WL. Chromosomal assignments of human 27-kDa heat shock protein gene family. Somat Cell Mol Genet. 1989 Mar; 15(2):167-71. PMID: 2538929.
      View in: PubMed
    161. Fuqua SA, Merkel DE, McGuire WL. Laboratory aspects of multidrug resistance. Cancer Treat Res. 1989; 42:45-59. PMID: 2577107.
      View in: PubMed
    162. Merkel DE, Fuqua SA, McGuire WL. P-glycoprotein in breast cancer. Cancer Treat Res. 1989; 48:97-105. PMID: 2577143.
      View in: PubMed
    163. Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989 Jan 1; 49(1):145-8. PMID: 2562795.
      View in: PubMed
    164. Osborne CK, Ross CR, Coronado EB, Fuqua SA, Kitten LJ. Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9. PMID: 3167228.
      View in: PubMed
    165. Moretti-Rojas I, Fuqua SA, Montgomery RA, McGuire WL. A cDNA for the estradiol-regulated 24K protein: control of mRNA levels in MCF-7 cells. Breast Cancer Res Treat. 1988 May; 11(2):155-63. PMID: 3401605.
      View in: PubMed
    166. Merkel DE, Fuqua SA, Hill SM, McGuire WL. P-glycoprotein gene amplification or overexpression is not detected in clinical breast cancer specimens. Prog Clin Biol Res. 1988; 276:61-73. PMID: 2902641.
      View in: PubMed
    167. Fuqua SA, Moretti-Rojas IM, Schneider SL, McGuire WL. P-glycoprotein expression in human breast cancer cells. Cancer Res. 1987 Apr 15; 47(8):2103-6. PMID: 3828999.
      View in: PubMed
    168. Fuqua SA, Naso RB. A comparison of the intracellular precursor polyproteins of simian sarcoma-associated virus [SiSV(SiAV)] and three human virus isolates: HL23V, HEL12V and A1476V. J Gen Virol. 1982 Sep; 62 (Pt 1):49-63. PMID: 6290596.
      View in: PubMed
    FUQUA's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _